02 Aug 2004
The US Food and Drug Administration (FDA) has concluded that radio frequency ID-based wireless technologies should form a key weapon in the fight against the manufacture and importation of counterfeit drugs.
The watchdog said that it is bolstering its already stringent regulations by recommending the use of RFID to protect the integrity of the drug manufacturing and distribution process.
Industry analyst firm IDC predicted that, spurred on by the FDA recommendations, RFID adoption will increase rapidly in the pharmaceutical industry over the next three years.
"The adoption and common use of RFID at the case and shipping-pallet level is increasingly likely by 2007, and would help secure the integrity of the drug supply chain," said Richard Dean, programme director of infrastructure integration and support services at IDC.
"Technology is rapidly approaching the state at which pharmaceutical companies can reliably and affordably provide greater assurances that a product was manufactured safely and distributed under conditions that did not compromise its potency or legitimacy."
According to a recently published IDC study, anti-counterfeiting efforts will increasingly rely on RFID technology developed by consulting and integration firms.
Latest stories from Web
Related articles
Related jobs
Poll
What will be the biggest change to corporate technology in the future?
TFL director of Games transport Mark Evers discusses how the public transport network is preparing for this summer's event
Connect with V3.co.uk
The wrong printers, for the wrong tasks on the wrong contracts
Who leads the BI pack and who should we be watching out for?
HTML, CSS, Flash - Web Content Editor - Photoshop, Dreamweaver...
Biomass Programme Manager/Engineering/Supply Chain/Heavy...
Head of Compliance My client is currently seeking...
THis role is working for a multi national Financial organisation...
Keep up to date with the latest products, services and technologies from the world's leading IT companies. IThound.com brings you over 2,000 white papers, case studies and analyst reports.
Do you agree?